Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections -- Qualified Infectious ...

CARB-X announced today that it’s awarding $1.2 million to a research team at Harvard University to develop enhanced antibiotics for multidrug-resistant bacteria.

Gram-negative meningitis is a form of meningitis. The term gram-negative refers to a way of differentiating bacteria. This type of bacteria is typically resistant to drugs and most available ...

Scientists at Duke University report they have developed a synthetic antibiotic that could be effective against drug-resistant superbugs and bacteria such as Salmonella, Pseudomonas, and E. coli.

Abstract and Introduction Empirical Antimicrobial Therapy Against Gram-negative Pathogens Adverse Consequences Related to Combination Antimicrobial Use Conclusion References A recent retrospective ...

Please provide your email address to receive an email when new articles are posted on . Gram-negative bacteria comprise most of the CDC and WHO’s lists of critical and urgent antibiotic-resistant ...

In a recent study published in the journal Nature, researchers in the United States of America designed and discovered lolamicin, a selective antibiotic that targets the lipoprotein transport system ...

Drugmakers must focus on developing new antibiotics to fight hospital “superbugs” including meningitis and other infections that can resist last-line treatments, the World Health Organization (WHO) ...

Siderophores are low-molecular-weight, high-affinity iron-chelating compounds secreted by Gram-negative bacteria to acquire iron from their environment. Iron is essential for bacterial metabolism and ...

Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections Qualified Infectious Disease ...